Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
about
Pyruvate dehydrogenase kinase as a novel therapeutic target in oncologyLactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cellsCancer as a metabolic diseaseThe epigenetic landscape of acute myeloid leukemiaPhosphofructokinase 1 glycosylation regulates cell growth and metabolismMetabolomics annotates ABHD3 as a physiologic regulator of medium-chain phospholipidsIDH1 and IDH2 mutations in gliomasApplications of metabolomics in cancer researchStructural, kinetic and chemical mechanism of isocitrate dehydrogenase-1 from Mycobacterium tuberculosisThe common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarateMutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomasIdentification of a CpG island methylator phenotype that defines a distinct subgroup of gliomaIdentification of the 2-hydroxyglutarate and isovaleryl-CoA dehydrogenases as alternative electron donors linking lysine catabolism to the electron transport chain of Arabidopsis mitochondriaGatekeepers of chromatin: Small metabolites elicit big changes in gene expressionLinks between metabolism and cancerStable isotope-resolved metabolomics and applications for drug developmentHypoxia-inducible factors and the response to hypoxic stressPlant D-2-hydroxyglutarate dehydrogenase participates in the catabolism of lysine especially during senescenceExciting new advances in neuro-oncology: the avenue to a cure for malignant gliomaOncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenasesRecent advances in the molecular understanding of glioblastomaClinical significance of T cell metabolic reprogramming in cancerTargeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectivesMetabolic, autophagic, and mitophagic activities in cancer initiation and progressionMicroRNAs and oncogenic transcriptional regulatory networks controlling metabolic reprogramming in cancersMitochondrial metabolic remodeling in response to genetic and environmental perturbationsMolecular Imaging of Metabolic Reprograming in Mutant IDH CellsEpigenetic regulators and their impact on therapy in acute myeloid leukemiaGenetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 MutationAdvances in mass spectrometry-based clinical biomarker discoveryFunctions of TET Proteins in Hematopoietic TransformationCancer Metabolism and Drug ResistanceDysregulated metabolism contributes to oncogenesisSuccinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and EpigeneticsIn vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studiesMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateMechanisms and functions of Tet protein-mediated 5-methylcytosine oxidationCancer metabolism: key players in metabolic reprogrammingCerebral neoplasms in L-2 hydroxyglutaric aciduria: 3 new cases and meta-analysis of literature dataMolecular mechanisms for survival regulation of chronic myeloid leukemia stem cells
P2860
06e2b920f018ed1bf2bc8735b2ff7bb366b0e9522bf64771a78774c145295356ec325382ca90624388fe545633f7bdb0528d77dd5ebde4de6a2530fc8c4b571922b2742f9c82702a694043c6fdafb475bd93bf3d4642615bf4b0d96a7e74023155a7deeecafd0153f6fcef9a66792416c800dcf3a6bd6702d2d5e62f5a4462ce72ef5406ccbf6bbbd9c5ca19df761d0ca80cda0d5eb8a55d4fd56e744fa9501a
P248
Q21129303-87B7C073-5A94-4C13-ACFF-EB20FFBB1856Q21133953-6A37B7C6-FB8B-4758-813B-F322D7326024Q21245061-D8640D32-5516-4AD4-9456-04F4063BBDDCQ21284742-D0423728-DB5B-4375-9D3C-F74F97056D75Q24297510-6FF6B58A-1B8B-44FA-B28E-F99E21F3D2DBQ24338159-C2F018BC-96C1-4B61-A833-90C4172CB4D0Q24561928-8E3D6DE4-05C4-4FE6-B050-B65A50CFDDE4Q24600728-3DCED242-54A3-49F6-9BEC-0D29EA182EE0Q24602123-34A4EC72-3491-45F9-A422-085E8AD5DAA9Q24605258-5DC2DDD0-9B06-4862-BABE-DFD6FD5827D7Q24610836-C983293F-BD71-4930-9CCC-CF393B67F2B1Q24612429-DFF1D479-5553-4234-9EA5-55624508F006Q24616939-AF3E27D6-147E-40A4-B80D-01DE4F8C5665Q24622821-32D7BB63-0BE3-4A64-8A04-470ADDC92AD2Q24626229-BDAC9581-B1EB-4609-9392-704852A05BB0Q24629149-CE8539D4-5801-4E86-A0E9-B709D736E495Q24629323-1E86DC87-0B85-433F-AF42-42BB71212124Q24632201-9D82A0D6-6FAF-46D5-B50F-809863DCA1D0Q24632791-B50E4AE6-F88C-46FF-A0F4-36330B1AA2CFQ24632807-7706EBA3-57EB-426F-9B11-EE700A9BF19FQ24632928-C118DFCF-B35D-4686-95EB-D5B659C418D0Q26741974-71C8363C-4527-43D8-AE9C-9C3BC0953893Q26744441-5415688D-B656-46EE-824A-E1D145A2251CQ26745503-FD5712F6-ED3D-4F84-932E-946DECD0D513Q26745980-F1C2A9BD-9442-4F03-A9FC-11323A7280DAQ26747718-4F3FA3BE-B310-4EDB-9F3C-4FABE4BDEB9FQ26750861-295B3B8B-3441-45A9-BB82-B7AEBDA372D1Q26765402-3DBD871B-2FE4-4B77-AD5F-99A4C7655432Q26767392-2A72648C-82B3-4E76-8E7A-F4D69D36D965Q26770004-2D4B9E05-9AEF-4B3E-9233-715433AFAEC4Q26778323-32452738-9768-4722-BDDD-83F0C8AAC77BQ26782042-4C6EB406-F3AF-4B7D-8297-DA28B4D6BEC9Q26784630-764E67F0-7E9E-4C11-A728-DB3678B972BBQ26796203-F3AF5DE1-9670-4062-BB92-E63DF6E42DDEQ26820289-80F63180-1B20-4691-A927-3CA34085AFA7Q26822717-9A07ACF3-18FC-46CA-BA97-60F88F992650Q26823896-5A86FA63-9C12-4F88-AADC-9E0EB9B123F5Q26827663-C7F18A09-3A93-4F4B-9C07-2EEDC08BE2ADQ26827985-18FFE9E2-9CDE-4797-AA84-A1A3DC57C03EQ26828528-08F6C976-31FB-4D5B-BD79-36BE14377785
P2860
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
@ast
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
@en
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
@en-gb
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
@nl
type
label
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
@ast
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
@en
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
@en-gb
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
@nl
prefLabel
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
@ast
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
@en
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
@en-gb
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
@en
P2093
Bryson D Bennett
Craig B Thompson
David W White
Edward M Driggers
Hyun Gyung Jang
Joshua D Rabinowitz
Katharine E Yen
Kevin M Marks
Lenny Dang
Marie C Keenan
P2860
P2888
P304
P3181
P356
10.1038/NATURE08617
P407
P577
2009-12-01T00:00:00Z
P6179
1016136939